What happened with ARGX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
argenx SE’s commercial business centers on VYVGART and its injectable formulations, used for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) where approved. In Japan, the franchise also treats immune thrombocytopenia (ITP), under the name VYVDURA. It sells through its own sales force in the United States, Japan, Europe and Canada. Most product sales come from the United States, and a small group of U.S. customers accounts for most of those sales.
Patients’ access depends on government and commercial health payors covering treatment and reimbursing enough of its cost. In Greater China, Zai Lab holds exclusive development and commercialization rights to efgartigimod, the drug behind VYVGART; argenx receives royalties and sales-based milestone payments there.
argenx has no internal manufacturing capability and relies on outside manufacturers, including Lonza and Fujifilm, to supply its medicines. It is developing VYVGART for additional diseases and other drug candidates, but these uses and products require clinical development and regulatory approval before sale. Approvals are specific to each market and may restrict which diseases or patient groups it can treat.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
argenx’s results hinge on VYVGART adoption in gMG and CIDP; watch UCB’s RYSTIGGO, an important FcRn rival missing from this list.
Immunovant, Inc. could bring new competition to argenx’s VYVGART with drugs targeting the same FcRn pathway in myasthenia gravis, CIDP and other autoimmune diseases, but it has no product-sales revenue yet. Watch IMVT-1402’s trials in generalized myasthenia gravis and CIDP for progress toward that competition.
Johnson & Johnson’s IMAAVY already competes with argenx’s VYVGART for generalized myasthenia gravis patients; it sells prescription medicines to hospitals, wholesalers and other healthcare buyers. Its nipocalimab development in CIDP and Sjögren’s disease could extend that competition into more of argenx’s treatment areas.
AstraZeneca’s Alexion business sells medicines that block complement, competing with argenx’s VYVGART for myasthenia gravis patients.
argenx depends on Halozyme Therapeutics, Inc.’s enzyme and licensed ENHANZE technology to help its under-the-skin efgartigimod injections disperse and absorb, and pays royalties on those products’ sales. Halozyme’s royalties from argenx products are therefore tied to sales of these formulations, not the whole VYVGART franchise.
Grifols sells immunoglobulin medicines made from human plasma that compete with argenx’s VYVGART, particularly for CIDP patients. Its reports of immunoglobulin discounting as customers become more price-sensitive flag the pricing competition VYVGART faces alongside these treatments.
Zai Lab sells argenx’s efgartigimod in Greater China—mainland China, Hong Kong, Taiwan and Macau—and its sales generate royalties and sales-based milestone payments for argenx. Watch its annual efgartigimod net sales there, the revenue line that directly determines those payments.
Viridian Therapeutics, Inc. is developing VRDN-006 and VRDN-008 against the same FcRn target as argenx’s marketed and experimental treatments. Progress on those two candidates is the relevant competitive signal for argenx, rather than Viridian’s separate thyroid eye disease licensing revenue.
Amgen and argenx sell biologic medicines competing for generalized myasthenia gravis patients. Amgen sells mainly through pharmaceutical wholesalers in the United States, so its news about this patient group is more relevant to VYVGART than its overall medicine sales.
Takeda’s immunoglobulin treatments compete with argenx’s VYVGART for CIDP patients and in other overlapping autoimmune treatment settings.
Sanofi’s development of riliprubart for CIDP could bring competition to argenx’s approved VYVGART and its broader pipeline of drugs targeting complement.
Cartesian Therapeutics, Inc.’s experimental Descartes-08 could offer myasthenia gravis patients an alternative to argenx’s VYVGART: it collects each patient’s cells, modifies them and returns them to the physician for infusion. Watch its trial results for efficacy and durability; this is a cell therapy still in development, not a commercial medicine.
Vor Biopharma Inc. is developing licensed telitacicept for autoimmune diseases including myasthenia gravis and Sjögren’s disease, creating potential competition for argenx’s efgartigimod treatments.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda’s report can show demand for its immunoglobulin treatments among people with CIDP, who may also be treated with argenx’s VYVGART.
Look at Takeda’s comments on sales and demand for its immunoglobulin treatments. Steady or stronger demand would show that this treatment option competing with VYVGART remains attractive, increasing the competitive pressure argenx faces for CIDP patients. Weaker demand could ease that pressure, but would not prove patients switched to VYVGART.
Halozyme Therapeutics, Inc. earningsHALO
Halozyme’s report can show how royalties from argenx’s under-the-skin efgartigimod formulations are changing, reflecting those formulations’ sales—not the whole VYVGART franchise.
Look for Halozyme’s disclosure of royalties from argenx products. Higher royalties mean the under-the-skin formulations are generating more royalty-linked sales, while argenx owes more under the arrangement. Lower royalties mean this route contributes less to both companies; they do not establish how intravenous VYVGART or the franchise overall is selling.
Zai Lab Limited earningsZLAB
Zai Lab’s report can show its efgartigimod sales in Greater China, which directly determine argenx’s royalties and sales-based milestone payments from that licensed territory.
Look for Zai Lab’s annual net sales of efgartigimod in Greater China. Higher sales mean more royalties for argenx and may trigger sales-based milestone payments; lower sales mean a smaller contribution from this licensed business. This is Zai Lab’s territory, not argenx’s sales in other markets.
Grifois, S.A. earningsGRFS
Grifols’ report can show whether it is discounting its immunoglobulin treatments more as customers become price-sensitive, a signal of pricing pressure on argenx’s VYVGART in CIDP.
Look for Grifols’ comments on immunoglobulin discounts and customers’ price sensitivity. Deeper discounts would show competing treatments using price to win customers, which could make it harder for argenx to maintain VYVGART pricing. Fewer discounts would suggest less pressure from this source, but would not establish argenx’s net prices or reimbursement terms.
